Neuropore Therapies, Inc. is a San Diego-based biopharmaceutical company dedicated to discovering innovative therapeutics that target the underlying causes of neurodegenerative diseases, with the mission of halting their progression. Their current clinical trials include the Phase 2 study of UCB0599 in patients with early-stage Parkinson's disease, and they have recently received a substantial grant from The Michael J. Fox Foundation for Parkinson's Research to support the development of their TLR2 program.
With a team of experts and strategic partnerships with corporate foundations and academic institutions, Neuropore Therapies is well-positioned to make significant advancements in the field of neurodegenerative disease research. Their publications highlight the promising effects of their small molecule, NPT200-11, in a transgenic mouse model of Parkinson's disease, demonstrating their commitment to finding potential therapeutic solutions. Located in San Diego, California, Neuropore Therapies is dedicated to making a positive impact on the lives of individuals affected by neurodegenerative diseases.
Generated from the website